Vera has a BAFF/APRIL B-Cell modulator based IgAN candidate called Atacicept, which has delivered 2b results and is in the early stage of a pivotal phase 3 study ORIGIN 3. This candidate could eventually offer a clinical filtration benefit for IgAN patients like Tarpeyo.